Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 1/20 | 0.63 |
| ▸ | TSHR | P16473 | 1/20 | 0.63 |
| ▸ | CA1 | P00915 | 4/20 | 0.60 |
| ▸ | CA2 | P00918 | 4/20 | 0.60 |
| ▸ | MAPT | P10636 | 3/20 | 0.56 |
| ▸ | MEN1 | O00255 | 2/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.56 |
| ▸ | NPC1 | O15118 | 2/20 | 0.56 |
| ▸ | RAB9A | P51151 | 2/20 | 0.56 |
| ▸ | POLB | P06746 | 1/20 | 0.56 |
| ▸ | CES2 | O00748 | 2/20 | 0.53 |
| ▸ | CES1 | P23141 | 2/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.53 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.53 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.52 |
| ▸ | PARP1 | P09874 | 1/20 | 0.50 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.50 |
| ▸ | PARP2 | Q9UGN5 | 1/20 | 0.50 |
| ▸ | PARP4 | Q9UKK3 | 1/20 | 0.50 |
| ▸ | ELANE | P08246 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7967084 | 1.00 | TP53 (0.63) | TP53TSHRCA1CA2MAPT | |
| SCHEMBL249567 | 1.00 | TP53 (0.63) | TP53TSHRCA1CA2MAPT | |
| SCHEMBL14420469 | 1.00 | TP53 (0.63) | TP53TSHRCA1CA2MAPT | |
| SCHEMBL698454 | 1.00 | TP53 (0.63) | TP53TSHRCA1CA2MAPT | |
| SCHEMBL935315 | 1.00 | TP53 (0.63) | TP53TSHRCA1CA2MAPT | |
| SCHEMBL10016798 | 0.93 | NPSR1 (0.62) | TP53TSHRCA1CA2MAPT | |
| SCHEMBL10016797 | 0.93 | NPSR1 (0.62) | TP53TSHRCA1CA2MAPT | |
| SCHEMBL13701278 | 0.90 | CA1 (0.53) | TP53TSHRCA1CA2MAPT | |
| SCHEMBL13943243 | 0.90 | CA1 (0.53) | TP53TSHRCA1CA2MAPT | |
| SCHEMBL25881959 | 0.90 | CA1 (0.53) | TP53TSHRCA1CA2MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9000158-B2 | Process for preparing levosimendan and intermediates for use in the process | CIPLA LIMITED (IN) | 2015-04-07 | — | — | US | disclosed |
| US-9000158-B2 | Process for preparing levosimendan and intermediates for use in the process | CIPLA LIMITED (IN) | 2015-04-07 | — | — | US | disclosed |
| US-20120165524-A1 | Process for Preparing Levosimendan and Intermediates for Use in the Process | CIPLA LIMITED (IN) | 2012-06-28 | — | — | US | disclosed |
| US-20120165524-A1 | Process for Preparing Levosimendan and Intermediates for Use in the Process | CIPLA LIMITED (IN) | 2012-06-28 | — | — | US | disclosed |
| WO-2011007123-A1 | PROCESS FOR PREPARING LEVOSIMENDAN AND INTERMEDIATES FOR USE IN THE PROCESS | CIPLA LIMITED (IN) | 2011-01-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120165524-A1 | Process for Preparing Levosimendan and Intermediates for Use in the Process | CYP3A5, HTR5A, CYP2D6 | TP53 4672/4885TSHR 456/4885CA1 2522/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.